[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"kidney-transplant-recipients\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:kidney-transplant-recipients":29},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,7,0,[8,44,74,101,135,157,189],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":32,"lastUpdatePostDateStruct":33,"startDateStruct":36,"completionDateStruct":38,"leadSponsor":40,"locationsCount":43},"100583868","phase-4-eduction-in-immunosuppressive-regimen-among-kidney-transplant-recipients-patients-admitted-to-the-intensive-care-unit-for-septic-shock-andor-acute-respiratory-failure-100583868",false,"NCT06881927","Eduction in ImmunoSuppressive Regimen Among Kidney Transplant Recipients Patients Admitted to the Intensive Care Unit for Septic Shock and\u002For Acute Respiratory Failure","Reduction in ImmunoSuppressive Regimen Among Kidney Transplant Recipients Patients Admitted to the Intensive Care Unit for Septic Shock and\u002For Acute Respiratory Failure: a Multicenter, Open-label, Phase IIb Randomized Controlled Trial","REDIS","Inclusion Criteria:\n\n* \\- Adult patients, aged 18 years-old and over,\n* Kidney transplant recipients, with transplantation occurring more than 3 months prior to ICU admission\n* Patients admitted to the ICU in the setting of:\n\n  * Septic shock (sepsis requiring vasopressor support, with or without hyperlactatemia),\n  * And\u002For acute respiratory failure of presumed infectious origin (invasive or non-invasive ventilation, FiO2 greater than or equal to 50%),\n* Patients treated with at least an immunosuppressive bitherapy (including steroids, calcineurin inhibitors, mTOR inhibitors, azathioprine, or mycophenolate mofetil),\n* Patients affiliated with a social health insurance protection scheme,\n* Patients able of understanding the objectives and risks related to the research and providing a dated and signed informed consent. If patient is unable to consent: consent from relatives will be searched, and if absent, an emergency procedure will be process.\n* Women of childbearing potential, provided they have a negative blood pregnancy test on the day of the inclusion visit.\n\nExclusion Criteria:\n\n* Minor patients,\n* Patients unable to consent: under legal protection measures, patients deprived of liberty,\n* Kidney transplant recipients treated with Belatacept due to the persistent effect of Belatacept, it is not possible to modulate this treatment in a short term period,\n* Patients with severe chronic graft dysfunction (glomerular filtration rate \\\u003C 20 ml\u002Fmin\u002F1.73m² according to the CKD-EPI formula in the month prior to admission),\n* Transplant renal recipients who have already resumed RRT (hemodialysis or peritoneal dialysis),\n* Multi-organ transplant recipients,\n* Pregnant women","ALL","18 Years",{"count":20,"type":21},212,"ESTIMATED","INTERVENTIONAL",[24],"PHASE4","Kidney transplantation is the treatment of choice for end-stage chronic kidney disease. Kidney transplantation is at the first rank of solid organ transplantation in France, with 3,376 grafts performed in 2022. Immunosuppressive therapy, required to prevent graft rejection, exposes graft recipients to complications related to decreased immunity, including opportunistic infections and neoplastic complications.\n\nAfter the earlt post-transplantation period, up to 10% of kidney transplant recipients will require admission to the intensive care unit (ICU). The main reasons for admission are septic shock and acute hypoxemic respiratory failure. ICU stay has a significant impact on these patients with a mortality rate reaching 40%, that remains increased even after ICU discharge. Furthermore, an impact on graft function has been demonstrated, with deterioration of graft function in 1\u002F3 of patients, and among those, up to one in two will require resumption of renal replacement therapy (RRT).\n\nAlthough the occurrence of septic shock or acute respiratory failure related to an infection is more common and severe, the optimal management strategy for immunosuppressors is not defined in kidney transplant recipients admitted to the ICU in those settings.\n\nMaintain a high level of immunosuppressive therapies may hinder the recovery from the acute critical condition. Furthermore, these treatments have a narrow therapeutic index; for instance, the management of calcineurin inhibitors is challenging in the ICU due to pharmacodynamic changes associated with the acute situation (distribution volume, organ failure) and the numerous potential drug interactions that carry inherent risks of overdose.\n\nthe investigators hypothesize that a reduction in the level of immunosuppressive treatments could promote recovery in kidney transplant recipients admitted to the ICU for septic shock and\u002For acute hypoxemic respiratory failure, without adversely affecting the risk of rejection or long-term renal prognosis.",[27,28,29,30],"Sepsis and Septic Shock","Acute Respiratory Failure","Kidney Transplant Recipients","Immunosuppressive Agents","RECRUITING","2026-06-03",{"date":34,"type":35},"2026-06-05","ACTUAL",{"date":37,"type":35},"2026-05-11",{"date":39,"type":21},"2029-06-01",{"name":41,"class":42},"University Hospital, Strasbourg, France","OTHER",1,{"id":45,"slug":46,"hasResults":11,"nctId":47,"briefTitle":48,"officialTitle":49,"acronym":50,"eligibilityCriteria":51,"healthyVolunteers":11,"sex":17,"minAge":52,"maxAge":4,"enrollmentInfo":53,"targetDuration":4,"studyType":22,"phases":55,"briefSummary":56,"conditions":57,"keywords":59,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":65,"lastUpdatePostDateStruct":66,"startDateStruct":68,"completionDateStruct":70,"leadSponsor":72,"locationsCount":43},"100573877","phase-4-neurocognitive-function-changes-with-extended-release-tacrolimus-among-older-kidney-transplant-recipients-100573877","NCT06751992","Neurocognitive Function Changes With Extended-Release Tacrolimus Among Older Kidney Transplant Recipients","Neurocognitive Function Changes With Once-Daily Extended-Release Tacrolimus (Envarsus XR) Conversion Compared to Twice-Daily Immediate Release Tacrolimus Maintenance Among Older Kidney Transplant Recipients","Neuro-KTR","Inclusion Criteria:\n\n* Able to give informed consent for participation in the study\n* Patients who have regular outpatient follow-up at the Massachusetts General Hospital (MGH) transplant center\n* ≥1 year since the latest kidney transplantation\n* On IR tacrolimus as maintenance therapy\n* At a stable therapeutic tacrolimus level (5-10 ng\u002Fml) over the last ≥3 months\n* Stable kidney function \\[\\\u003C20% variability between the last two estimated glomerular filtration rate (eGFR)\\]\n* Utilizing English or Spanish as the primary language\n\nExclusion Criteria:\n\n* Dual organ transplantation\n* Rejection within the last three months\n* History of moderate to severe dementia (defined by Dementia Severity Rating Scale ≥19)\n* History of Parkinson's disease\n* Decompensated liver disease\n* Active cancer\n* Uncontrolled depression or anxiety\n* Blindness\n* Deafness\n* Intellectual disabilities\n* Pregnancy\n* eGFR \\\u003C15 mL\u002Fmin\u002F1.73 m2 at the time of enrollment\n* Total bilirubin \\>3.0 mg\u002FdL","65 Years",{"count":54,"type":21},92,[24],"The objective of this randomized controlled study is to assess the neurocognitive outcomes between individuals using immediate-release (IR) tacrolimus (Prograf®) and those who were converted to extended-release tacrolimus (Envarsus XR) among older kidney transplant recipients (KTRs).",[29,58],"Old Age",[60,61,62,63,64],"Neurocognitive function","Tacrolimus","Kidney transplant recipients","Tremor","Insomnia","2026-05-26",{"date":67,"type":35},"2026-05-28",{"date":69,"type":35},"2026-03-17",{"date":71,"type":21},"2027-10-01",{"name":73,"class":42},"Massachusetts General Hospital",{"id":75,"slug":76,"hasResults":11,"nctId":77,"briefTitle":78,"officialTitle":79,"acronym":80,"eligibilityCriteria":81,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":82,"targetDuration":4,"studyType":22,"phases":84,"briefSummary":86,"conditions":87,"keywords":88,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":92,"lastUpdatePostDateStruct":93,"startDateStruct":95,"completionDateStruct":97,"leadSponsor":99,"locationsCount":43},"100511382","phase-2-the-efficacy-mechanism--safety-of-sodium-glucose-co-transporter-2-inhibitor--glucagon-like-peptide-1-receptor-agonist-combination-therapy-in-kidney-transplant-recipients-100511382","NCT05938712","The Efficacy, Mechanism & Safety of Sodium Glucose Co-Transporter-2 Inhibitor & Glucagon-Like Peptide 1 Receptor Agonist Combination Therapy in Kidney Transplant Recipients","A Two Arm, Open Label, Pilot Study to Evaluate the Safety and Efficacy of the Combined Use of Once Daily 10mg Dapagliflozin and Once Weekly 1.0mg Semaglutide in Kidney Transplant Recipients","HALLMARK","Inclusion Criteria:\n\n* Signed and dated written informed consent.\n* Patients aged ≥18 years with KTR\n* \\>3 months post kidney transplantation\n* Estimated glomerular filtration rate \\[eGFR\\] ≥20 ml\u002Fmin\u002F1.73m2\n* BP \\\u003C160\u002F100 and \\>90\u002F60 at screening\n* Body-mass index \\[BMI\\] between 18.5-40kg\u002Fm2\n* In patients with T2D or PTDM, HbA1c \\\u003C12.0%;\n\nExclusion Criteria:\n\n* Type 1 diabetes.\n* History of multi-organ transplant\n* Acute coronary syndrome, transient ischemic attack or stroke within 30 days prior to screening\n* Impending need for kidney biopsy or rapid decline in eGFR within 30 days prior to screening\n* Actively treated BK, CMV or EBV infection\n* Recurrent pyelonephritis or need for indwelling or self-catheterization\n* Prior amputation or ischemic rest pain\n* Women who are pregnant, nursing, or who plan to become pregnant whilst in the trial.\n* History of pancreatitis\n* Personal or family history or medullary thyroid cancer or MEN2B\n* History of unstable diabetic retinopathy within 1 year prior to screening\n* Use of SGLT2i or GLP-1RA within 30 days prior to screening.\n* Current and frequent episodes of hypoglycemia\n* Current history of DKA requiring medical intervention or hospitalization\n* With current risk of volume depletion, hypotension and\u002For electrolyte imbalance\n* With known or suspected hypersensitivity to semaglutide or related products\n* Patient not able to understand and comply with study requirements, based on Investigator's judgment.\n* Any other clinical condition that, based on Investigator's judgement, would jeopardize patient safety during trial participation or would affect the study outcome (e.g. immunocompromised patients, active malignancy, patients who might be at higher risk of developing genital or mycotic infections, patients with chronic viral infections, uncontrolled hypertension, cardiorenal and\u002For hepatorenal syndrome etc.).",{"count":83,"type":21},20,[85],"PHASE2","The study aims to determine the short-term efficacy, mechanisms and safety of 12 weeks of dapagliflozin and semaglutide combination therapy in 20 KTR, with and without T2D.",[29],[89,90,91],"Type 2 diabetes","SGLT2 inhibition","GLP-1 receptor agonist","2026-04-30",{"date":94,"type":35},"2026-05-01",{"date":96,"type":35},"2023-10-24",{"date":98,"type":21},"2028-03-01",{"name":100,"class":42},"University Health Network, Toronto",{"id":102,"slug":103,"hasResults":11,"nctId":104,"briefTitle":105,"officialTitle":106,"acronym":107,"eligibilityCriteria":108,"healthyVolunteers":109,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":110,"targetDuration":4,"studyType":22,"phases":112,"briefSummary":114,"conditions":115,"keywords":117,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":125,"lastUpdatePostDateStruct":126,"startDateStruct":128,"completionDateStruct":130,"leadSponsor":132,"locationsCount":134},"100633900","diode-laser-assisted-periodontal-therapy-in-kidney-transplant-recipients-100633900","NCT07532694","Diode Laser-Assisted Periodontal Therapy in Kidney Transplant Recipients","Periodontal Status in Kidney Transplant Patients and the Effectiveness of Adjunctive Diode Laser Therapy","KTRs","Inclusion Criteria:\n\n* Kidney transplant recipients aged 18 years or older.\n* Diagnosis of periodontitis according to the study case definition.\n* Medically stable and able to undergo non-surgical periodontal treatment.\n* Willing and able to provide written informed consent and attend follow-up visits.\n\nExclusion Criteria:\n\n* \\- Periodontal treatment or systemic antibiotic use within the predefined exclusion window in the protocol.\n* Acute oral infection requiring urgent treatment.\n* Pregnancy or lactation, if excluded by the approved protocol.\n* Serious systemic condition or clinical instability judged by investigators to preclude study participation.\n* Inability to comply with study procedures or follow-up schedule.",true,{"count":111,"type":21},80,[113],"NA","This randomized controlled trial evaluates the efficacy of diode laser-assisted non-surgical periodontal therapy in kidney transplant recipients with periodontitis. Eighty participants will be allocated to two parallel groups: scaling and root planing (SRP) with adjunctive diode laser therapy or SRP alone. Clinical periodontal parameters, blood biomarkers, radiographic findings, and subgingival microbiome profiles will be assessed at baseline and during follow-up. The study aims to determine whether adjunctive diode laser therapy provides superior clinical and biological improvement compared with SRP alone.",[116,29],"Periodontitis",[118,119,120,121,122,123,124],"diode laser","scaling and root planing","periodontal therapy","kidney transplantation","16S rRNA","microbiome","C-reactive protein","2026-04-09",{"date":127,"type":35},"2026-04-16",{"date":129,"type":35},"2025-12-09",{"date":131,"type":21},"2026-06-09",{"name":133,"class":42},"Military Hospital 103",2,{"id":136,"slug":137,"hasResults":11,"nctId":138,"briefTitle":139,"officialTitle":140,"acronym":4,"eligibilityCriteria":141,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":142,"targetDuration":4,"studyType":22,"phases":144,"briefSummary":146,"conditions":147,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":149,"lastUpdatePostDateStruct":150,"startDateStruct":152,"completionDateStruct":154,"leadSponsor":155,"locationsCount":43},"100493226","early-phase-1-pilot-trial-of-supplemental-vitamin-a-and-nicotinamide-100493226","NCT05702398","Pilot Trial of Supplemental Vitamin A and Nicotinamide","Pilot Trial of Supplemental Vitamin A and Nicotinamide and Levels of Blood Vitamin A and Nicotinamide","Inclusion Criteria:\n\n* 18 years old or greater;\n* Either History of 2 or more histologically confirmed invasive cutaneous SCCs in the past 2 years or\n* At least one previously billed Healthcare Common Procedure Coding System code 17004 (destruction of 15 or more benign or premalignant lesions of the integumentary system);\n* Understands, reads, and writes English proficiently.\n\nExclusion Criteria:\n\n* Liver disease;\n* Active peptic ulcer disease;\n* Recent myocardial infarction;\n* Hypotension;\n* Internal malignancy within past 5 years;\n* Renal impairment with eGFR\\\u003C15 mL\u002Fmin\u002F1.73 m2;\n* Being unable for follow up due to social reasons;\n* Gorlin's syndrome or other genetic skin cancer syndrome;\n* Huge number of current skin cancers;\n* Metastatic SCC or invasive melanoma within the past 5 years;\n* Pregnancy or lactation;\n* Need for ongoing carbamazepine use (which could have a possible interaction with NAM);\n* Use of acitretin or other oral retinoids within the past 6 months;\n* Use of supplemental NAM, niacin, vitamin A, or beta carotene within the past 6 months;\n* Field treatment for actinic keratoses (AKs) within the previous 4 weeks;\n* Use of topical steroids.",{"count":143,"type":21},30,[145],"EARLY_PHASE1","The goal of this clinical trial is to assess the feasibility and safety of oral nicotinamide (NAM; a derivative of vitamin B3 \\[niacin\\]) and vitamin A in a high-risk population of kidney transplant recipients with a history of skin cancer to generate preliminary data for future cancer prevention clinical trials.",[148,29],"Skin Cancer","2026-03-18",{"date":151,"type":35},"2026-03-20",{"date":153,"type":35},"2023-04-01",{"date":98,"type":21},{"name":156,"class":42},"Rhode Island Hospital",{"id":158,"slug":159,"hasResults":11,"nctId":160,"briefTitle":161,"officialTitle":162,"acronym":163,"eligibilityCriteria":164,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":165,"enrollmentInfo":166,"targetDuration":4,"studyType":22,"phases":168,"briefSummary":169,"conditions":170,"keywords":173,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":180,"lastUpdatePostDateStruct":181,"startDateStruct":183,"completionDateStruct":185,"leadSponsor":187,"locationsCount":43},"100621446","velocity-based-resistance-training-in-kidney-transplant-recipients-100621446","NCT07370727","Velocity-Based Resistance Training in Kidney Transplant Recipients","Effects of Velocity-Based Resistance Training on Renal Function and Metabolic Health in Kidney Transplant Recipients: Protocol for a Randomized Controlled Trial","VBRTKIDNEY","Inclusion Criteria:\n\n* Men and women aged 18 to 50 years.\n* Kidney transplant performed ≥12 months before enrollment.\n* Stable graft function in the previous 6 months (serum creatinine \\\u003C 1.5 mg\u002FdL, no rejection episodes).\n* Written medical clearance from a nephrologist to perform moderate-to-vigorous physical activity.\n* Signed informed consent.\n\nExclusion Criteria:\n\n* Active autoimmune disorders.\n* Recent coronary disease (≤6 months).\n* Severe musculoskeletal limitations incompatible with resistance training.\n* Diagnosis of diabetes mellitus (pre- or post-transplant).\n* Current active infection.\n* Use of immunosuppressive drugs with contraindications for exercise (e.g., mTOR inhibitors at baseline).","50 Years",{"count":167,"type":21},12,[113],"This randomized controlled trial aims to evaluate the effects of velocity-based resistance training on renal function and metabolic health in kidney transplant recipients. Participants will be randomized into two groups performing resistance training at different execution velocities (maximal intended vs. submaximal controlled). The intervention will last 12 weeks and include multi-joint exercises (squat, bench press, military press). Primary outcomes include renal function (serum creatinine, eGFR, blood urea nitrogen, uric acid) and metabolic markers (HDL, triglycerides, glucose, waist circumference, blood pressure). Secondary outcomes include muscle strength, force-velocity profile, anthropometry, physical activity, fitness perception, and adherence to immunosuppressive medication.",[29,171,172],"Metabolic Syndrome","Cardiovascular Risk Factors",[174,175,176,177,178,179],"Kidney Transplant","Renal Transplant","Velocity based resistance training","Metabolic Health","Exercise Intervention","Glomerular Filtration Rate (eGFR)","2026-01-21",{"date":182,"type":35},"2026-01-27",{"date":184,"type":35},"2025-10-29",{"date":186,"type":21},"2027-12-31",{"name":188,"class":42},"Fundación Universitaria del Area Andina",{"id":190,"slug":191,"hasResults":11,"nctId":192,"briefTitle":193,"officialTitle":194,"acronym":195,"eligibilityCriteria":196,"healthyVolunteers":11,"sex":17,"minAge":197,"maxAge":198,"enrollmentInfo":199,"targetDuration":4,"studyType":22,"phases":201,"briefSummary":202,"conditions":203,"keywords":204,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":211,"lastUpdatePostDateStruct":212,"startDateStruct":214,"completionDateStruct":216,"leadSponsor":218,"locationsCount":43},"100578082","exercise-and-diet-effects-in-reducing-cardiovascular-risk-in-kidney-transplant-recipients-100578082","NCT06806670","Exercise and Diet Effects in Reducing Cardiovascular Risk in Kidney Transplant Recipients","Effects of Exercise and Dietary Counselling in Reducing the Cardiovascular Risk Score in Kidney Transplant Patients: KT- LIFESTYLE Study","KT-LIFESTYLE","Inclusion Criteria:\n\n* Clinically stabilised male and female kidney transplant patients (assessment by the referring transplant centre)\n* Minimum age, 30 years;\n* Maximum age, 69 years;\n* Period since transplantation: from 6 months (subject to clinical stability being achieved) to 10 years;\n* Organ function: eGFR (CKD-EPI formula) ≥ 30 mL\u002Fmin\u002F1.73m ;2\n* Obtaining informed consent;\n\nExclusion Criteria:\n\n* Patients unable to follow the prescription,\n* Recent acute cardiovascular event (\\\u003C 2 months),\n* Unstable angina,\n* Hyperkinetic\u002Fhypokinetic arrhythmias not controlled by therapy, and with signs of haemodynamic impairment,\n* Severe aortic stenosis,\n* Heart failure NYHA class III-IV, FE \\\u003C 40%,\n* Acute illnesses that limit physical activity,\n* Severe hypertension (basal BP ≥200\u002F110 mm Hg),\n* Neuro-musculo-skeletal pathologies that may be aggravated by exercise,\n* Patients unwilling to change lifestyle;\n* Any form of substance abuse, psychiatric disorder or condition that, according to the investigator, can complicate communication between doctor and patient;\n* Pregnant women.","30 Years","69 Years",{"count":200,"type":21},275,[113],"The goal of this clinical trial is to assess whether, over an observation period of 3 years, there is a reduction in cardiovascular risk, and the extent of this reduction, in a group of adult kidney transplant patients undergoing tailored exercise combined with dietary counselling compared to a group of patients following the 'standard of care'.",[29],[205,206,207,208,209,210],"exercise","diet","cardiovascular risk","kidney transplant recipients","gut microbiota","lifestyle","2025-01-28",{"date":213,"type":35},"2025-02-04",{"date":215,"type":35},"2025-01-07",{"date":217,"type":21},"2031-01",{"name":219,"class":42},"IRCCS Azienda Ospedaliero-Universitaria di Bologna"]